Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D7DU
|
|||
| Former ID |
DIB007160
|
|||
| Drug Name |
VLTS-589
|
|||
| Synonyms |
Deltavasc; Del-1 gene therapy, Valentis; Gene therapy (Del-1, PINC), Valentis
Click to Show/Hide
|
|||
| Indication | Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73.9; ICD-9: 443.9] | Phase 2 | [1] | |
| Company |
Valentis
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00068133) Trial of VLTS-589 in Subjects With Intermittent Claudication. U.S. National Institutes of Health. | |||
| REF 2 | AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.